Coronavirus Stocks Flying Up, Mesoblast Share Price to Follow? (ASX:MSB)

Today we look at the Mesoblast Ltd [ASX:MSB] share price in light of the recent successes of other coronavirus ‘solution’ stocks. A famous quote comes to mind…

In the midst of every crisis, lies great opportunity’ — Albert Einstein.

The current pandemic currently gripping the global economy proves no different.

Perhaps you have heard of Harvard medical professor Timothy Springer, who earned a whopping AU$1.2 billion during the coronavirus crisis.

Professor Springer has Massachusetts-based company Moderna Inc [NASDAQ:MRNA] to thank for his newly accumulated wealth.

The biotechnology firm attempting to develop a vaccine for the novel coronavirus has seen its share price rocket by 162% this year.

Springer is not the only one who has made big profits from the global pandemic.

Electronic document signing service DocuSign Inc [NASDAQ:DOCU] and video conferencing tool Zoom Video Communications Inc [NASDAQ:ZM] have both gone gangbusters with so many people working from home.

‘The Coronavirus Portfolio’: The two-pronged plan to help you deal with the financial implications of COVID-19. Download your free report here.

Mesoblast closer to a cure

What we can learn from the late Albert Einstein and Professor Springer, is that opportunity can present itself at any time.

You don’t have to be invested in Moderna either.

Take Melbourne-based biotech Mesoblast for instance.

The developer of biological products for regenerative medicine today announced some impressive results in their quest for a COVID-19 cure.

MSB is developing a therapy for COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS).

Clinical trials reported an 83% survival rate in ventilator-dependent COVID-19 patients, with 75% successfully coming off ventilator support within a median of 10 days.

In contrast, only 9% of ventilator-dependent COVID-19 patients at a major referral hospital network in New York City were able to come off ventilator support when treated…

Source Link

Advertisements